Lu-177-Herceptin: a potential radioimmunoconjugate for treatment of HER2 metastatic breast cancer

Her2/neu expressing breast cancers are the most aggressive type of breast cancers. It is associated with worst prognosis. The treatment of widespread metastatic disease is still a challenge despite the advancement in technology. From the past few decades radiolabeled antibodies have emerged as promising targets for targeted treatment of widespread metastatic disease. Trastuzumab is a FDA approved monoclonal antibody used routinely in clinic in combination with other chemotherapy drugs for treatment of Her2 breast cancer. This study was aimed at evaluating the targeting ability of radioimmunoconjugate, Lu-177-Trastuzumab in patients with metastatic HER2 breast cancer disease as a palliative treatment option in these patients. Lu-177-trastuzumab can be developed with good radiolabeling yield in a hospital radiopharmacy. The radioimmunoconjugate may be a potential treatment option for palliative treatment of HER2 positive metastatic breast cancer patients